AstraZeneca's aldosterone synthase inhibitor baxdrostat reduced blood pressure by 14 mmHg over 12 weeks, the pharma has said ...
Novel Aldosterone Synthase Inhibitor Lorundrostat Shows Promise for Uncontrolled Hypertension in CKD
A new aldosterone synthase inhibitor added to SGLT2 inhibitors reduces uncontrolled blood pressure in patients with chronic kidney disease, according to the results of a phase 2 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback